molmed

Investors

Board of Directors approved the first hal-year financial report ended June 30th, 2017

Board of Directors approved the first hal-year financial report ended June 30th, 2017 ▾

Investors

MolMed and Dompé signed strategic commercialization and supply agreements for Zalmoxis® in Europe

MolMed and Dompé signed strategic commercialization and supply agreements for Zalmoxis® in Europe ▾

Investors

MolMed S.p.A.: mandate of Liquidity Provider assigned to Mediobanca

MolMed S.p.A.: mandate of Liquidity Provider assigned to Mediobanca ▾

Investors

MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories

MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories ▾

Investors

MolMed provides update on Zafiride Conditional Marketing Authorisation application

MolMed provides update on Zafiride Conditional Marketing Authorisation application ▾

Investors

MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017

MolMed’s Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017 ▾

News & Events

Stay update

Annual meeting of the Italian Group of Bone Marrow Transplant (GITMO) ▾

Annual meeting of the Italian Group of Bone Marrow Transplant (GITMO)

Location: Hotel Michelangelo - Milan, Italy

MolMed at this event: Sponsoring a lecture (in Italian) on the state of the art and perspectives of genetically modified T cell-based adoptive immune-therapy, held by professor Fabio Ciceri

Investors

MolMed and Megapharm enter into a license and distribution agreement on Zalmoxis® in Israel Pdf

MolMed and Megapharm enter into a license and distribution agreement on Zalmoxis® in Israel Pdf ▾

Investors

Outcome of shareholders’ meeting of April 10, 2017

Outcome of shareholders’ meeting of April 10, 2017 ▾

Investors

Ordinary shareholders' meeting April 10 2017

Ordinary shareholders' meeting April 10 2017 ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.